Keros Therapeutics Inc (KROS)

Oct 21, 2025

Technical Reactions to KROS Trends in Macro Strategies - news.stocktradersdaily.com

Oct 21, 2025

Oct 21, 2025

Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? - Yahoo Finance

Oct 21, 2025

Oct 21, 2025

Can Keros Therapeutics Inc. recover in the next quarterMarket Risk Summary & Community Consensus Picks - newser.com

Oct 21, 2025

Oct 21, 2025

Using flow based indicators on Keros Therapeutics Inc.July 2025 Update & AI Powered Market Entry Strategies - newser.com

Oct 21, 2025

Oct 20, 2025

Keros Therapeutics Inc. stock trendline breakdownWeekly Investment Recap & AI Optimized Trading Strategy Guides - newser.com

Oct 20, 2025

Oct 20, 2025

Keros Therapeutics (NASDAQ:KROS) Trading Up 10.8%Still a Buy? - MarketBeat

Oct 20, 2025

Oct 20, 2025

Why Keros Therapeutics Inc. stock remains undervaluedLong Setup & Accurate Entry/Exit Alerts - newser.com

Oct 20, 2025

Oct 20, 2025

Published on: 2025-10-20 18:43:57 - newser.com

Oct 20, 2025

Oct 20, 2025

Reversal indicators forming on Keros Therapeutics Inc. stockPortfolio Risk Report & Weekly High Potential Stock Alerts - newser.com

Oct 20, 2025

Oct 20, 2025

What hedge fund activity signals for Keros Therapeutics Inc. stockTrade Ideas & Long-Term Investment Growth Plans - newser.com

Oct 20, 2025

Oct 20, 2025

Can trapped investors hope for a rebound in Keros Therapeutics Inc.July 2025 Catalysts & Reliable Momentum Entry Alerts - newser.com

Oct 20, 2025

Oct 20, 2025

Keros Therapeutics Inc. stock daily chart insightsMarket Performance Recap & Capital Efficient Trade Techniques - newser.com

Oct 20, 2025

Oct 20, 2025

Keros Therapeutics (KROS) Launches $194.4 Million Stock Buyback - GuruFocus

Oct 20, 2025

Oct 20, 2025

Wells Fargo & Company Initiates Coverage on Keros Therapeutics (NASDAQ:KROS) - MarketBeat

Oct 20, 2025

Oct 20, 2025

Will breakout in Keros Therapeutics Inc. lead to full recovery2025 Fundamental Recap & Reliable Price Breakout Alerts - newser.com

Oct 20, 2025

Oct 20, 2025

Keros Therapeutics (KROS) Initiates Tender Offer for Share Buyback - GuruFocus

Oct 20, 2025

Oct 20, 2025

Keros Therapeutics Launches Tender Offer for Up to $194.4 Million of Shares - MarketScreener

Oct 20, 2025

Oct 20, 2025

Keros Therapeutics (KROS) Initiates $194.4M Stock Buyback Progra - GuruFocus

Oct 20, 2025

Oct 20, 2025

Keros Therapeutics launches $194.4 million share repurchase tender offer - Investing.com

Oct 20, 2025

Oct 20, 2025

Keros (KROS) launches fixed-price cash tender offer for shares - Stock Titan

Oct 20, 2025

Oct 20, 2025

$194.4M Tender Offer — Keros Therapeutics to Repurchase at $17.75; Part of $375M Program. Expires Nov. 18, 2025 - Stock Titan

Oct 20, 2025

Oct 19, 2025

Historical volatility pattern of Keros Therapeutics Inc. visualized2025 Valuation Update & High Accuracy Trade Alerts - newser.com

Oct 19, 2025

Oct 18, 2025

Keros Therapeutics (NASDAQ:KROS) Major Shareholder Sells $84,975,125.25 in Stock - MarketBeat

Oct 18, 2025

Oct 18, 2025

Chipmakers Recap: Is Keros Therapeutics Inc. stock supported by strong fundamentalsWeekly Profit Report & Real-Time Volume Analysis - nchmf.gov.vn

Oct 18, 2025

Oct 18, 2025

What momentum indicators show for Keros Therapeutics Inc. stockQuarterly Profit Summary & Daily Entry Point Alerts - nchmf.gov.vn

Oct 18, 2025

Oct 18, 2025

Is Keros Therapeutics Inc. stock supported by strong fundamentalsWeekly Trade Review & Accurate Buy Signal Notifications - nchmf.gov.vn

Oct 18, 2025

Oct 18, 2025

Is Keros Therapeutics Inc. stock a buy on dipsWatch List & Advanced Swing Trade Entry Alerts - nchmf.gov.vn

Oct 18, 2025

Oct 17, 2025

Earnings visualization tools for Keros Therapeutics Inc.Trade Ideas & Daily Stock Momentum Reports - newser.com

Oct 17, 2025

Oct 17, 2025

Sarcopenia Market Insights Highlight Expanding Outlook Till - openPR.com

Oct 17, 2025

Oct 17, 2025

Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com

Oct 17, 2025

Oct 17, 2025

Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m By Investing.com - Investing.com Australia

Oct 17, 2025

Oct 17, 2025

Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m - Investing.com India

Oct 17, 2025

Oct 17, 2025

KROS insiders file Form 4; Pontifax funds report stock sales - Stock Titan

Oct 17, 2025

Oct 17, 2025

How to recover losses in Keros Therapeutics Inc. stock2025 Price Action Summary & Verified Momentum Stock Ideas - newser.com

Oct 17, 2025

Oct 17, 2025

Is Keros Therapeutics Inc. stock poised for growthSwing Trade & Community Consensus Picks - newser.com

Oct 17, 2025

Oct 17, 2025

Keros Therapeutics, Inc. (KROS) Stock Analysis: Unpacking a 67% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews

Oct 17, 2025

Oct 17, 2025

Forecasting Keros Therapeutics Inc. price range with options dataWall Street Watch & Long-Term Capital Growth Ideas - newser.com

Oct 17, 2025

Oct 16, 2025

Keros Therapeutics (NASDAQ:KROS) Major Shareholder Adar1 Capital Management, Llc Sells 5,389,264 Shares - MarketBeat

Oct 16, 2025

Oct 16, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛

Oct 16, 2025

Oct 16, 2025

Keros Therapeutics Unveils Major Capital Return Initiative Amid Leadership Reshuffle - AD HOC NEWS

Oct 16, 2025

Oct 15, 2025

Keros Therapeutics Sparks Market Interest With Nasdaq Futures - Kalkine Media

Oct 15, 2025

Oct 15, 2025

Keros Therapeutics Plans Major Buyback And Tender Offer - Finimize

Oct 15, 2025

Oct 15, 2025

Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m By Investing.com - Investing.com Nigeria

Oct 15, 2025

Oct 15, 2025

Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m - Investing.com

Oct 15, 2025

Oct 15, 2025

Keros Therapeutics (NASDAQ:KROS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat

Oct 15, 2025

Oct 15, 2025

Keros Therapeutics Announces Plan for Return of $375 Million In Excess Capital - citybiz

Oct 15, 2025